Overview

Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma

Status:
Recruiting

Trial end date:
2023-01-01

Target enrollment:
0

Participant gender:
All

Summary

Zoledronic acid is an adjuvant treatment for primary osteosarcoma. Zoledronic acid has been widely used in the treatment of metastatic bone tumors. In addition to its inhibition of tumor osteoclasis, it also produces certain killing of tumor cells. effect. Foreign studies have shown that zoledronic acid also has a killing effect on osteosarcoma and has a certain inhibitory effect on distant metastasis. We hope that it can reduce tumor recurrence and lung metastasis through this study.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Treatments:

Zoledronic Acid

Criteria

Inclusion Criteria:

- Patients with osteosarcoma who were diagnosed with initial pathology and pathology
were excluded from lung metastasis or other metastatic lesions by CT and total body
emission-computed tomography, and patients with standard chemotherapy were evaluated.

Exclusion Criteria:

- Pulmonary metastasis, pregnancy or lactation, renal insufficiency (creatinine
clearance <70 ml/min/1.73 m2), liver dysfunction, obvious oral disease, and unsuitable
for bisphosphonate treatment after evaluation, have been found. With diseases that
still require hormone therapy, abnormal blood system, heart disease